Physician profile
Keith A Waddle
NPI 1720058589
$488.79
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $131.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $200.20 | 2019-2020 | |
| Janssen Biotech, INC. | $99.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.41 | 2019-2020 | |
| Pfizer INC. | $25.10 | 2019 | |
| Allergan, INC. | $24.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.35 | 2019-2020 | |
| Boston Scientific Corporation | $18.75 | 2019 | |
| Braintree Laboratories, INC. | $17.10 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.73 | 2019 | |
| Gilead Sciences, INC. | $13.26 | 2019 | |
| Daiichi Sankyo INC. | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Waddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.